Argymhellodd canllawiau NICE, a gyhoeddwyd ym mis Gorffennaf 2013, ddefnyddio Aflibercept i drin AMD Gwlyb ac fel y cyfryw cytunais y dylai fy swyddogion ymgysylltu â’r offthalmolegwyr yng Nghymru sy’n trin AMD Gwlyb ar hyn o bryd ac sy’n defnyddio’r cyffur Lucentis. Gofynnais iddynt ystyried goblygiadau argymhellion NICE a’r costau cysylltiedig ar sail Cymru gyfan.
The NICE guidance, issued in July 2013, recommended the use of Aflibercept for Wet AMD treatment and as such I agreed that my Officials should engage with the ophthalmologists in Wales currently undertaking treatment of Wet AMD using the drug Lucentis. I asked them to consider the implications of the NICE recommendations and associated costs on an all-Wales basis.